| Bioactivity | SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1]. |
| Name | SARS-CoV-2-IN-15 |
| CAS | 1580-42-3 |
| Formula | C14H9ClF3NO2 |
| Molar Mass | 315.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295. |
SARS-CoV-2-IN-15
CAS: 1580-42-3 F: C14H9ClF3NO2 W: 315.67
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclo
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.